rezolutebio.com的 10 大竞争对手

clinicaltrials.gov

ClinicalTrials.gov is a website and online database of clinical research studies and information about their results

coherus.com

Check out job opportunities at Coherus Oncology, a commercial-stage company advancing next-generation combination therapies for people living with cancer.

biopharmadive.com

The latest pharma news for biotech and biopharmaceutical professionals

fiercebiotech.com

A central nervous system (CNS) tumor has prompted the FDA to

oncolink.org

oncolink, the web's first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials

investor.ironwoodpharma.com

Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Ironwood’s pending acquisition of VectivBio, expired at 11:59 p.m., Eastern Time, on June 15, 2023. As previously announced on May 22, 2023, Ironwood commenced a tender offer to purchase all of VectivBio’s outstanding ordinary shares for $17.00 per share in cash. The tender offer is scheduled to expire one minute past 11:59 p.m., Eastern Time, on June 28, 2023, unless extended in accordance with the transaction agreement and the applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). The expiration of the HSR waiting period

clinicaltrialsarena.com

Stay updated on the latest trends and innovations in the clinical trials industry. Explore expert insights and news to stay ahead. Visit us now!

bioprocessonline.com

In this segment of the Bioprocess Online Live event IND Success: Navigate Through The Regulatory Gray, NDA Partners Regulatory Affairs Expert Consultant Daniela Drago, Ph.D. and Umoja Biopharma VP of Regulatory Affairs Helen Kim offer several of their go-to resources for guidance when preparing an IND submission.

targetedonc.com

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.